A CRA expert was retained in an antitrust class action matter on behalf of a branded pharmaceutical manufacturer in which plaintiffs alleged inappropriate listings of patents in the FDA’s Orange Book under the Hatch-Waxman Act, sham patent litigation, and attempted monopolization. CRA’s expert economic analyses demonstrated the branded pharmaceutical competed broadly with other products and that plaintiffs’ but-for model lacked validity.
Contested ground: Early competition and market dynamics in generative AI
CRA Competition experts, Andrea Asoni, Matteo Foschi, and Oliver Latham, teamed up with Chiara Farronato of Harvard Business School to reflect on developments...